Climara

What it is

Climara is a brand-name once-weekly transdermal patch that delivers 17β-estradiol — the bioidentical form of estrogen the ovaries made before menopause — through the skin into the bloodstream. It is the longest-wear estradiol patch approved by the FDA in the United States.

The Climara estradiol patch is a clear, flexible adhesive round that is worn on the lower abdomen (below the waistline) or upper buttock and is changed once every 7 days. It is FDA-approved for moderate-to-severe vasomotor symptoms (hot flashes and night sweats), moderate-to-severe symptoms of vulvar and vaginal atrophy (genitourinary syndrome of menopause), and prevention of postmenopausal osteoporosis.

Climara is available in five strengths: 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day. Most Kindr patients start at 0.05 mg/day and titrate up or down based on symptom response and tolerability.

Because Climara uses bioidentical estradiol (not synthetic conjugated estrogens like Premarin), it is chemically identical to the estrogen produced by a healthy premenopausal ovary. This is what most patients mean when they ask for "bioidentical HRT."

How it works

The Climara patch releases estradiol continuously through the skin over 7 days, maintaining a steady serum estradiol level rather than the peaks and troughs of oral estrogen. Steady levels are what allow the hypothalamic thermoregulatory center to reset, which is the mechanism that reduces hot flashes and night sweats — typically by 75–80% within 8–12 weeks (NAMS 2022).

Transdermal delivery bypasses the liver "first-pass" metabolism that occurs with oral estrogen. This is the central clinical reason major guidelines — NAMS 2022, Endocrine Society, and the International Menopause Society — prefer transdermal estradiol like Climara over oral estrogen for patients with elevated risk of venous thromboembolism (blood clot), migraine with aura, high triglycerides, gallbladder disease, or known liver impairment.

Restored estradiol also protects bone mineral density (an FDA-approved indication for Climara), restores vaginal epithelium and lubrication, supports sleep architecture by reducing nocturnal vasomotor episodes, and stabilizes mood for many patients through direct estrogen-receptor effects in the brain.

Who it's for

• Healthy women under age 60 or within 10 years of menopause onset with bothersome hot flashes, night sweats, sleep disruption, or genitourinary symptoms
• Women who prefer once-weekly application over a daily pill or a twice-weekly patch (Vivelle-Dot, Minivelle, Alora)
• Postmenopausal women at elevated risk of osteoporosis without contraindication to estrogen
• Patients with elevated cardiovascular or thrombotic risk factors where transdermal is preferred over oral (obesity, migraine with aura, high triglycerides, gallbladder disease, family history of clotting)
• Women with a uterus (must be combined with a progestogen — typically micronized progesterone at bedtime — for endometrial protection)

Who should not take it

• Personal history of breast cancer or other estrogen-sensitive cancer
• Active or recent (within 12 months) blood clot, stroke, transient ischemic attack, or heart attack
• Active liver disease
• Undiagnosed abnormal vaginal bleeding
• Known or suspected pregnancy
• Known hypersensitivity to estradiol or patch adhesive

Common side effects

• Mild skin irritation, redness, or itching at the patch site (rotate placement each week — alternating lower-abdomen sites — to minimize)
• Breast tenderness, mild bloating, or headache during the first 4–6 weeks (usually resolves as the dose stabilizes)
• Spotting or breakthrough bleeding, especially during the first 3–6 months of a combined estrogen-plus-progestogen regimen
• Nausea (less common with transdermal than oral estrogen)
• Occasional patch adhesion issues with hot tubs, prolonged sun exposure, or heavy sweating (Climara is designed to stay on through showering, swimming, and normal exercise)

Evidence summary

• FDA-approved indications: moderate-to-severe vasomotor symptoms associated with menopause, moderate-to-severe symptoms of vulvar and vaginal atrophy, and prevention of postmenopausal osteoporosis.
• NAMS 2022 Hormone Therapy Position Statement: transdermal estradiol (including Climara) is the preferred estrogen route in patients with elevated VTE risk, migraine with aura, high triglycerides, or gallbladder disease.
• Endocrine Society 2015 Clinical Practice Guideline: transdermal estrogen is associated with a lower risk of venous thromboembolism than oral estrogen in observational and randomized data.
• ESHRE/IMS 2016: transdermal estradiol at physiologic replacement doses does not appear to increase VTE or stroke risk above baseline in healthy, appropriately selected women under 60.
• Climara pivotal trials demonstrated ~80% reduction in hot flash frequency by week 12 vs placebo, with sustained bone mineral density preservation over 2 years at the 0.05 mg/day dose.

Brand-name vs compounded

Climara is an FDA-approved brand-name product. Many Kindr patients use compounded alternatives prepared by a state-licensed 503A pharmacy when a custom dose, custom combination, or different delivery form is clinically preferable. Both pathways are available through Kindr — your provider will recommend based on your individual needs.

FAQ

Sources

• NAMS 2022 Hormone Therapy Position Statement
• ACOG: Menopausal Symptom Management
• U.S. Food & Drug Administration
• Climara FDA prescribing information
• Endocrine Society Menopause Guideline

Other medications

This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.